Baseline Expression Levels of WNT8B, KRT2, and TTLL13P are associated with abrocitinib response in atopic dermatitis

Our real-world data from 96 patients confirms that abrocitinib induces rapid clinical improvement and broadly downregulates genes in cytokine and JAK-STAT signaling pathways. We also identified that patients achieving EASI-90 response had a distinct baseline profile characterized by lower Th2 cytokines and a specific transcriptomic signature of high WNT8B and low TTLL13p and KRT2 expression. This signature was validated as a predictive biomarker in an independent cohort, suggesting it can be used to stratify patients for a higher likelihood of achieving minimal disease activity with abrocitinib.